Because the MEK kinases are the only known activator of ERK1/2, and because ERK1/2 are the only known substrates of MEK and play a critical role in cell proliferation and tumorigenesis (35, 36), inhibition of MEK has been considered a relatively specific and effective approach in cancer therapy. Here, MAPK3 is linked to cancer.